β-catenin (Phospho-Ser715) Antibody

#11594

Number: 11594

Amount: 100μg/100μl

Form of Antibody: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl,0.02% sodium azide and 50% glycerol.

Storage/Stability: Store at -20℃/1 year

Immunogen: synthetic phosphopeptide corresponding to residues surrounding Ser715 of human β-catenin

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phospholation site.

Specificity/Sensitivity: β-catenin (Phospho-Ser715)antibody detects endogenous levels of β-catenin only when phospholated at Serine715 .

Reactivity: Human

Applications:

Predicted MW: 95KD

WB **:**1:500~1:1000 IHC:1:50-200



Detection of β-catenin Ser715 phosphorylation in WT β-catenin but not β-catenin S715 mutant. HEK 293T cells were transfected with indicated plasmids cells with Wnt3a treatment for 8 h. The cells were subjected to immunoprecipitation with an anti-Myc antibody followed by immunoblotting with indicated antibodies.



IHC staining with anti-β-catenin Ser715 phosphorylation antibodies was carried out on human GBM specimens. Scale bars: 200 μm.

Background :Aberrant activation of b-catenin in the nucleus has been implicated in a variety of human cancers. TRIM33 interacts with and ubiquitylates nuclear b-catenin. Moreover, protein kinase Cd, which directly phosphorylates b-catenin at Ser715, is required for the TRIM33 – b-catenin interaction. In human glioblastoma specimens, endogenous TRIM33 levels are inversely correlated with b-catenin, we can abolish tumour cell proliferation and tumorigenesis by degrading nuclear b-catenin [1] .

Reference:[1] Xue J, Chen Y, Wu Y, Wang Z, Zhou A, Zhang S, Lin K, Aldape K, Majumder S, Lu Z, Huang S. Tumour suppressor TRIM33 targets nuclear β-catenin degradation. ***Nat Commun.*** 2015 Feb 2;6:6156. doi: 10.1038/ncomms7156.